

Resource Summary Report

Generated by [NIF](#) on Aug 30, 2026

22Rv1

RRID:CVCL_1045

Type: Cell Line

Proper Citation

RRID:CVCL_1045

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1045

Proper Citation: RRID:CVCL_1045

Description: Cell line 22Rv1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Prostate carcinoma

Defining Citation: [PMID:10462204](#), [PMID:12725112](#), [PMID:14518029](#), [PMID:14518030](#), [PMID:15486987](#), [PMID:19403664](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:21248069](#), [PMID:22460905](#), [PMID:23117885](#), [PMID:23671654](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:27271795](#), [PMID:27397505](#), [PMID:28145883](#), [PMID:28928128](#), [PMID:30629668](#), [PMID:30787054](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31006810](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:31978347](#), [PMID:35839778](#), [PMID:38892296](#)

Comments: Virology: Contains at least 10 integrated copies of xenotropic murine leukemia virus-related virus (XMRV) genome and produces a high titer of the virus (PubMed=19403664; PubMed=30629668)., Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: 22Rv1

Synonyms: 22RV1, 22Rv-1, 22rV1, CWR-22rv1, CWR22-Rv1, CWR22R-V1, CWR22-R1, CWR22Rv1, CWR22R

Cross References: BTO:BTO_0002999, CLO:CLO_0001199, CLO:CLO_0001200, EFO:EFO_0002095, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2505, BCRC:60545, BioGRID_ORCS_Cell_line:821, BioSample:SAMN03471600, BioSample:SAMN03472052, BioSample:SAMN05292447, BioSample:SAMN07710012, BioSample:SAMN07710013, BioSample:SAMN07710014, BioSample:SAMN07710015, BioSample:SAMN07710016, BioSample:SAMN07710017, BioSample:SAMN07710018, BioSample:SAMN10988315, cancercellines:CVCL_1045, CCRID:3101HUMSCSP5022, CCRID:3101HUMTCHu100, CCRID:4201HUM-CCTCC00288, CCRID:5301HUM-KCB07031YJ, CCTCC:GDC0288, Cell_Model_Passport:SIDM00499, ChEMBL-Cells:ChEMBL3308004, ChEMBL-Targets:ChEMBL612657, CLS:305037, Cosmic:924100, Cosmic:1028699, Cosmic:1071480, Cosmic:1075276, Cosmic:1172629, Cosmic:1330911, Cosmic:1689707, Cosmic:1995323, Cosmic:2537791, Cosmic:2580126, Cosmic:2651766, Cosmic:2669170, Cosmic-CLP:924100, DepMap:ACH-000956, DSMZ:ACC-438, DSMZCellDive:ACC-438, ECACC:05092802, EGA:EGAS00001000978, ENCODE:ENCBS070BKF, ENCODE:ENCBS383WOY, ENCODE:ENCBS596KKM, ENCODE:ENCBS626QQL, ENCODE:ENCBS737IZN, ENCODE:ENCBS822DIG, GDSC:924100, GEO:GSM91926, GEO:GSM525793, GEO:GSM648815, GEO:GSM827396, GEO:GSM886837, GEO:GSM887900, GEO:GSM1374375, GEO:GSM1633317, GEO:GSM1633318, GEO:GSM1633319, GEO:GSM1669565, GEO:GSM3145592, GEO:GSM3145703, IARC_TP53:18887, IGRhCellID:22Rv1, KCB:KCB_200731YJ, LiGeA:CCELE_229, LINC_S_LDP:LCL-1145, Lonza:1442, PharmacDB:22RV1_12_2019, PRIDE:PXD030304, Progenetix:CVCL_1045, PubChem_Cell_line:CVCL_1045, Ubigen:YC-C012, Wikidata:Q54583380

ID: CVCL_1045

Hierarchy: cvcl_3967

Record Creation Time: 20220427T215041+0000

Record Last Update: 20260830T001842+0000

Ratings and Alerts

No rating or validation information has been found for 22Rv1.

No alerts have been found for 22Rv1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 959 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#).

Nayak S, et al. (2026) Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degradar and Antagonist, for the Treatment of Advanced Prostate Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(1), 224.

Kim M, et al. (2026) Bone Metastatic Progression of Prostate Cancer Is Regulated by TRIM28-LDHA-Mediated Metabolism. *Molecular cancer research : MCR*, 24(2), 93.

Kalla J, et al. (2026) Biobank of genetically defined murine prostate cancer tumoroids uncovers oncogenic pathways and drug vulnerabilities driven by PTEN-loss. *Cell reports methods*, 6(4), 101370.

Shi W, et al. (2026) Targeting FANCD2 to overcome enzalutamide resistance in prostate cancer. *Cancer & metabolism*, 14(1).

Cunningham ML, et al. (2026) PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration-resistant prostate cancer. *Molecular oncology*, 20(2), 369.

Lindsey GL, et al. (2026) Structural and mechanistic analysis of covalent ligands targeting the RNA-binding protein NONO. *Cell chemical biology*, 33(2), 256.

Gordon N, et al. (2026) PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer. *Molecular oncology*, 20(6), 1626.

O'Loughlin TA, et al. (2026) mTORC1 activity suppresses ferroptosis through a SCARB1-dependent HDL-tocopherol uptake pathway. *Molecular cell*, 86(8), 1546.

Dong G, et al. (2026) Discovery of SKP2-Recruiting PROTACs for Target Protein Degradation. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(20), e15159.

Singh KB, et al. (2026) Restoration of Immune Surveillance in Prostate Cancer Prevention by Sulforaphane in Hi-Myc Mice. *Molecular carcinogenesis*, 65(6), 677.

Tian Y, et al. (2026) Fine mapping regulatory variants by characterizing native CpG methylation with nanopore long-read sequencing. *HGG advances*, 7(1), 100532.

Wilson A, et al. (2026) Inhibiting stearyl-CoA desaturase suppresses bone metastatic prostate cancer by modulating cellular stress, mTOR signaling, and DNA damage response. *FEBS letters*, 600(7), 1043.

Rodrigues SD, et al. (2026) Suppression of de novo lipogenesis and dietary PUFA supplementation inhibit prostate cancer progression. *bioRxiv : the preprint server for biology*.

Huang J, et al. (2026) The FOSB-IGFBP5-IGF-1 axis: a novel regulatory pathway that suppresses prostate cancer growth. *Cancer gene therapy*.

Li H, et al. (2026) YEATS2 promotes DNA repair and induces anoikis resistance by enhancing chromatin accessibility to drive prostate cancer metastasis. *Oncogene*, 45(11), 971.

Koo KM, et al. (2026) Rapid Decentralized Prostate Cancer Risk Stratification by Portable Liquid Biopsy Analysis within a Clinical Biosensor Validation Framework. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(13), e12126.

Bidkar AP, et al. (2026) Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody-Drug Conjugates. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(8), 1540.

Liu C, et al. (2026) Androgen Receptor-Induced Lactoferrin Accelerates Prostate Tumorigenesis Through Modulating Ferroptosis. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(37), e20109.

Susa T, et al. (2026) Androgen Signaling Represses Homeobox C9, an Inhibitor of Androgen Receptor, in Prostate Cancer Cells. *International journal of molecular sciences*, 27(4).

Zhang C, et al. (2026) GNL3 Orchestrates AR Transcriptional Programs to Drive Castration-Resistant Prostate Cancer and Immune Evasion. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(26), e16411.